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MODIFICATIONS AND MEDICATIONS TO IMPROVE ALZHEIMER’S DISEASE
FROM TYPE 2 DIABETES
Ashley Robinson
ABSTRACT
Alzheimer’s Disease (AD) and Type 2 Diabetes (T2D) are chronic conditions increasing
in prevalence that impact the daily lives of those afflicted with them. AD and T2D are linked
through the pathophysiology of insulin resistance. Thus, there are intersections that can allow the
management of T2D to improve the treatment and prevention of AD. Modifiable risk factors,
such as diet and physical activity level, play important roles in the health of T2D patients as well
as in preventing AD. Medications traditionally used in the treatment of T2D, such as metformin,
pioglitazone, and insulin, are being examined for use in the new context of treating AD.
Improving patient education on chronic diseases and modifiable risk factors, as well as
continuing research into applications of drugs to treat and prevent AD, can reduce much of the
suffering associated with AD and other chronic illnesses, such as T2D.
KEYWORDS
Alzheimer’s disease (AD) – Type 2 Diabetes (T2D) – MIND diet – DASH diet – Mediterranean
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INTRODUCTION
Alzheimer’s disease (AD) is the most common form of dementia, affecting around 5.5
million people in the United States (1). The progressive cognitive decline it causes creates much
suffering for patients and caregivers. Due to the fact that the number of elderly individuals
continues to grow in the United States, and that the incidence of AD doubles every five years
starting at age sixty, the number of adults in the United States diagnosed with AD can be
expected to continue to grow (1). By 2050, it has been predicted that the prevalence of AD could
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increase to sixteen million instances (2). As a result of the suffering of those currently facing AD
and the potential for more in the increasing numbers of those who will have it in the future, AD
is a subject of research into effective treatment and prevention methods.
Prevention strategies are needed because before symptoms become noticeable to the
patient or clinician, changes happen in the brain that suggest the disease is present (3). This
means that there is a window for treatment that is not being accessed with current protocols.
Hence, prevention is especially important. Once AD begins damaging the brain, there is a
significant gap before treatment takes place. Even once treatment starts, there is not much that
can be done to stall the steady progression of the disease. In treatment today, approaches to halt
or delay the onset or progression of AD are needed. Currently, the largest class of medications
prescribed for the treatment of AD is acetylcholinesterase inhibitors, which slow the breakdown
of acetylcholine. This compensates for the destruction of cholinergic neurons in the basal nucleus
of Meynert that characterizes AD.
Current research being done on AD investigates its links to Type 2 Diabetes (T2D).
Unlike Type 1 Diabetes, T2D is an insulin resistance in the body, not a complete lack of insulin
production from the pancreas. T2D, like AD, is another chronic illness that affects millions in the
United States. Paralleling the growing elderly population and the rise in AD, an increase in T2D
is correlated with the continuing increase in the obese population (4). Both T2D and AD are
chronic illnesses that impact the daily lives of patients afflicted with them. Viewing AD as an
insulin resistance in the brain, there are multiple aspects of T2D treatment and prevention that
can be applicable in this new context, such as exercise, diet, and medication. First, I will consider
the pathology connecting T2D and AD, and then explain the intersections in treatment and
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prevention between the two diseases. Finally, I will provide recommendations for further
research and protocols.
LINKING ALZHEIMER’S DISEASE AND TYPE 2 DIABETES
Risk
Age is well-known as the biggest risk factor for dementia. Beyond this, patients with T2D
are at a higher risk for AD, as T2D is a recognized risk factor for AD. It has been shown that
T2D patients, even with good blood glucose level control, have declines in executive control
functions and working memory compared to those without T2D; however, these declines are not
as great as in those with AD (5). These findings support the idea that T2D patients are at risk for
developing AD (5).
Conversely, impaired insulin signaling in the hypothalamus increases the risk for
developing diabetes in a mouse model of AD, suggesting that AD can also affect T2D (6). In
another mouse model of both AD and T2D, it has been found that the diseases, over time,
concurrently increase pathologies of both individual diseases (7). Metabolic dysfunction, cortical
size reduction, and an amyloid-β production shift to a more toxic form were seen (7).
Pathology
One theory that links AD and T2D is insulin resistance. T2D is known to be a peripheral
insulin resistance, while AD has been proposed to be an insulin resistance of the brain (8). In the
periphery, insulin is responsible for the uptake of glucose from the blood stream into cells to be
used for energy. In the brain, insulin and insulin-like growth factor-1 (IGF-1) affect the central
nervous system and regulate learning, memory, energy use, and neuronal health (9). Insulin is
produced in the periphery by the pancreas and is transported across the blood-brain barrier (8).
Insulin receptors are found throughout the periphery, but in the brain are most prevalent in areas
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such as the cerebral cortex, hippocampus, and amygdala (9). Insulin has been linked to improved
cognition based on its effects in the hippocampus (8). The hippocampus is one of the areas that
feature the most neuronal death in AD. Insulin resistance has been found in the hippocampus of
AD patients who do not have T2D (10).
The two hallmark characteristics of AD, plaques and tangles, have been linked to insulin
signaling in the brain. Tangles are made up of abnormally folded and phosphorylated tau protein.
Insulin and IGF-1 have been found to regulate tau phosphorylation (8). Plaques are made of
amyloid-β protein. Defective insulin signaling increases the rate of amyloid-β protein production
and aggregation, leading to the characteristic plaques of AD (11). Additionally, amyloid-β
proteins disrupt insulin signaling, leading to an upregulating cycle of protein production and
plaque formation (10). Disrupted insulin signaling has also been liked to neuronal death through
excitotoxicity, neuroinflammation, and the disruption of energy production in neurons (8).
Plausibility
Despite the research linking AD and T2D through insulin resistance, arguments have
been made against this relationship. It is debated whether insulin resistance is a cause or effect of
AD (12). This becomes more difficult to determine, as researchers report that there is a lack of
studies that examine whether diabetes more commonly occurs before or after the diagnosis of
AD (12). Additionally, links to Type 1 Diabetes, not just T2D, are being explored (13). Links to
both Type 1 Diabetes and T2D have led researchers to propose that AD is “Type 3 Diabetes,” as
it may not correlate so clearly with T2D (13). Although current literature provides complications
to the link between AD and T2D, the evidence that has been found suggests that T2D may serve
as an important key to treating and preventing AD.
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INTERSECTIONS IN TREATMENT
As a result of their similar pathology, there are multiple intersections in treatment that
can be applied from T2D to AD. Once diagnosed with T2D, it is important for patients to control
their condition, as rapid progression and more severe diabetes increases dementia risk (14).
Controlling T2D has a two-fold effect on AD: not only do treatments for T2D directly affect a
patient’s risk for AD due to their shared pathology, but controlling T2D also lowers the risk for
AD because T2D is a risk factor for AD. Conversely, treatments aimed at reducing the incidence
of AD have the potential to be useful in T2D treatments.
Exercise
Weight loss is one of the first steps taken to control T2D as a result of its links with
obesity. It has been shown that physical activity may play a role in preventing AD. Various types
and durations of exercise, from walking and running to weight training, have been shown to be
linked with improvements in biomarkers related to AD including TNF-α, ROS, and ceramides
(15). Increases in these biomarkers as seen with T2D have effects on AD and other forms of
dementia, including insulin resistance of the brain and other subsequent effects. Exercise has
been found to have protective effects on cognition and neural function, including neurogenesis
(15).
Exercise is often something that is lacking in a typical T2D patient, as well as in the
elderly. The American College of Sports Medicine recommends that individuals over the age of
sixty-five and those over the age of fifty with a chronic disease, such as T2D, perform regular
physical exercise of various types ranging from balance to aerobic exercises (16). These
recommendations would include Type 2 Diabetics and others at risk for AD and other forms of
dementia. Mini-Mental State Examination scores have been found to be negatively correlated
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with increased pulse rate, an indirect measure of physical fitness, in elderly subjects (17). This
suggests that regular physical activity would have a benefit on cognition and Mini-Mental State
Examination scores, as it would decrease pulse rate. This idea is reinforced by the finding that
older individuals who engaged in 150 or more minutes per week of at least moderate physical
activity were forty percent less likely to develop AD (18).
Diet
Dietary changes are some of the most important factors in the treatment of T2D, as diet is
a modifiable risk factor for diabetes and other chronic conditions. It is essential for Type 2
Diabetics to control their carbohydrate intake in order to maintain their blood glucose levels.
Specifically, it is important to consume carbohydrates low on the glycemic index to prevent
spikes in blood glucose levels. A high fat and high cholesterol diet can be detrimental to any
person’s health, but is especially detrimental to those with T2D who need to regulate their weight
and blood sugar. In an animal model, it has been shown that a diet high in cholesterol and fat
leads to cognitive impairment and biomarkers of AD, such as higher levels of tau protein (19).
There are many diets that have been investigated in order to improve health. The
Mediterranean diet has long been known as a healthy diet that is related to decreased incidences
of cardiovascular disease and diabetes, and the MedDietScore has been used to determine that
increased adherence to this diet leads to a reduced risk of coronary heart disease (20, 21).
Additionally, it is thought to have protective effects with regards to cognition (21, 22). It has not
only been linked to a reduced risk of AD, but has been found to slow cognitive decline (21). This
diet is culturally based on the consumption of fruits, vegetables, fish, legumes, and olive oils
(21). Another diet linked to cognitive protection and other health benefits is the DASH diet, or
Dietary Approaches to Stop Hypertension. The DASH diet focuses on eating more fruits,
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vegetables, and low fat dairy items in order to reduce hypertension. The DASH diet was also
found to be related to higher executive function-memory-learning scores, which was enhanced
by weight loss (23). Both diets, with their focus on vegetable consumption and limited intake of
lean meats, will provide benefits not only for cardiovascular disease and cognition, but also for
T2D, which would benefit from the reliance on low glycemic index foods and low fat intake.
Increased adherence to the Mediterranean diet or the DASH diet has been shown to decrease
both the risk and incidence of AD (22).
Based on the benefits seen from the Mediterranean and DASH diets, the MIND diet, or
the Mediterranean-DASH Intervention for Neurodegenerative Delay, was developed. The MIND
diet emphasizes plant-based nutrition and limits consumption of animal and high fat foods.
Specific foods, such as berries and leafy, green vegetables, which are thought to improve brain
health, are emphasized (22). The MIND diet has been shown to reduce the risk of AD in
participants who followed the dietary protocol to at least a moderate degree (22). A correlation
between the MIND diet and global cognitive measures has been found, meaning this diet is
linked to slowing cognitive decline (24). The rate of cognitive decline reduction was shown to be
the equivalent of being seven and a half years younger for participants who adhered most
strongly to the MIND diet (24).
Beyond the Mediterranean, DASH, and MIND diets, other diets that can decrease the risk
for chronic and age-related diseases. One of these is another culturally based diet, the Okinawan
diet. The diet is based on the consumption of low glycemic index carbohydrates like vegetables
and soybean-based foods. Additionally, it is based on a consumption of seafood and small
amounts of other lean meats (25). The Okinawan diet is similar to the Mediterranean and DASH
diets, as it reduces the risk of cardiovascular disease (25). Additionally, based on the fact that it
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emphasizes foods low on the glycemic index, like sweet potatoes, it also is a good choice for
diabetics (25). Based on its similarities to other diets that have been shown to prevent and slow
cognitive declines related to neurodegenerative diseases, it is likely that the Okinawan diet would
show similar benefits.
Overall, a Western diet high in meat, fatty dairy products, and sugary sweets is related to
an increase in AD incidence, as meat consumption has been found to be a large contributor to
one’s risk of AD (26). Meat consumption is also related to other chronic conditions, such as
T2D. In countries moving from previous diets to the Western diet, such as Japan, rates of AD
rose six percent over a twenty-three year period (27). Based on the benefits seen previous
studies, transitioning from the Western diet to healthier diets such as the Mediterranean, DASH,
MIND, or Okinawan diets has the potential, I believe, to decrease chronic conditions including
both T2D and AD.
Medication
Many Type 2 Diabetics turn to medication to control their blood glucose levels when
dietary choices and physical exercise are not sufficient. One of the most popular of these is
metformin. Metformin activates AMP-activated protein kinase (AMPK), decreases glucose
production by liver cells, and increases glucose uptake in skeletal muscle cells (28). Overall, this
lowers blood glucose levels. In mice, metformin has been shown to protect against amyloid-β
protein plaques in the hippocampus and high fat diets (29). Amyloid-β plaques are one of the
distinguishing features of AD, and the hippocampus is one of the major sites of neuronal loss in
AD and is involved in learning and memory.
Research is being done to investigate AMPK as a target for the treatment of
neurodegenerative diseases. Activation of AMPK by an agonist, such as 5-aminoimidazole-4-
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carboxamide riboside (AICAR), has been shown to improve both motor function and memory in
mice (30). AMPK is activated by exercise as well as AICAR; however, in the case of the elderly
who are most at risk for AD, getting the protective effect of physical activity on AD and benefits
to cognition from physical exercise may not be possible due to their physical frailty. In addition,
activation of AMPK by metformin may provide benefits to neurological function in a manner
similar to AICAR, helping to prevent AD and improve motor function in a population at an
increased risk for AD.
Another medication used to control blood sugar levels is pioglitazone. This medication is
a peroxisome proliferator activated receptor γ (PPARγ) agonist. Activation of PPARγ has been
shown to prevent the deposit of amyloid-β proteins and plaques by decreasing the activation of
beta secretase (31). Beta secretase is one of the enzymes involved in converting amyloid
precursor protein into amyloid-β protein. Long-term use of pioglitazone has been shown to lower
the risk of dementia by forty-seven percent below that of patients without diabetes (32). If they
did not receive pioglitazone, diabetic patients exhibited a twenty-three percent increased risk for
developing dementia (32).
Some T2D patients use insulin to control their blood sugar. Although more commonly
associated with Type 1 Diabetes, insulin can be used in patients for whom lifestyle choices and
oral medications are not sufficient to control their blood glucose levels. Benefits to AD patients
have been shown with intranasal insulin (33). Although it has only been studied in a mouse
model of AD, intranasal insulin reduces anxiety and improves cognitive deficits (33).
Additionally, intranasal insulin has beneficial effects on the biomarkers of AD. Specifically,
intranasal insulin reduces amyloid-β plaque levels and deposits in the brain by modifying
amyloid precursor protein in a non-amyloidogenic way through the use of alpha secretase. (33).
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Amyloid-β plaques, along with tau tangles, are one of the major hallmarks of AD. Additionally,
intranasal insulin enhances neurogenesis in the hippocampus (33).
RECOMMENDATIONS
This is not an exhaustive list of all of the connections between AD and T2D; more
research is necessary to fully examine the links between these two diseases. Specifically, more
research is needed with human subjects. Investigations currently being done on T2D medications
being used for AD and long-term models of T2D and AD are being done in mice. The current
use of animal models to investigate neurodegenerative diseases like AD is useful due to the
ability to use animals to perform trials and manipulations that would be unethical in humans.
Additionally, animal models provide results much faster than human trials, as the lifespan of
animals is shorter and disease conditions can be induced in animals. Despite these benefits, more
research is needed in human subjects since results in animal models are not always applicable to
humans.
Beyond research, it is necessary to provide patient education on the subjects of diet and
exercise in regards to the prevention of AD and T2D. Prevention and early intervention are the
best ways to reduce the suffering caused by neurodegenerative diseases like AD. Lifestyle
choices such as those related to nutrition and physical activity decrease the risk of T2D, which in
turn lowers the risk of AD. HbA1C level, an indicator of blood glucose control over time, can be
lowered through a patient’s choices in regards to self-management of their disease. In addition to
nutrition and exercise, this includes taking medication as prescribed (34). Outside of T2D,
lifestyle choices can reduce the risk of AD outright due to the related pathology of AD and T2D.
As such, the intersections between AD and T2D lead to the potential of broader applications of
these links to a larger population beyond that of Type 2 Diabetics. For example, although it is
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well established that T2D is a risk factor for AD, it has been shown that increased blood glucose
levels are a risk factor for dementia, even in those without T2D (35).
CONCLUSION
AD is the most common form of dementia and only continues to become more
widespread. T2D is another chronic illness that continues to increase in prevalence. Due to their
similar insulin resistance pathology, AD and T2D affect each other over time and are risk factors
for each other. As a result of their similarities, managements and preventative measures for T2D
can fill in the current gaps in the treatment and prevention of AD. Modifiable risk factors are the
easiest ways for patients at risk for AD to lessen the chance of developing the neurodegenerative
disease. Increasing levels of physical activity and transitioning from a Western diet to healthier
diets will allow them to reduce their risk. At the same time, these measures help to control blood
glucose levels to control or prevent the onset of T2D. Beyond modifiable risk factors in the
hands of the patient, medications used to treat T2D can be used to treat AD. Overall, increased
patient education and continued research can greatly reduce and prevent the suffering caused by
both T2D and AD.
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